$EDIT News
Last published 1d ago
- 1d agoEDITGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - EDITAS MEDICINE INCEarnings Call TranscriptsGood afternoon, and thank you for joining Guggenheim at our third annual Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Gilmour O'Neill, President and CEO of
- 2d agoEDITEditas Medicine, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoEDITEditas Medicine Announces Third Quarter 2026 Results and Business UpdatesGlobeNewswireCompany received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented...
- 2d agoEDITEditas Medicine Announces Third Quarter 2026 Results and Business UpdatesGlobeNewswireCompany received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C
- 4w agoEDITEditas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceGlobeNewswireCAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two
- 1mo agoEDITEditas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with HyperlipidemiaGlobeNewswirePhase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability
- 2mo agoEDITEditas Medicine Reports Inducement Grants to New Chief Medical OfficerGlobeNewswireCAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an
- 2mo agoEDITEditas Medicine Appoints Dan Ory, M.D., as Chief Medical OfficerGlobeNewswireExperienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as Editas advances
- 2mo agoEDITEditas Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that
- 3mo agoEDITEditas Medicine Announces Second Quarter 2026 Results and Business UpdatesGlobeNewswireEDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a)
- 3mo agoEDITEditas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.GlobeNewswireCAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the
- 5mo agoEDITEditas Medicine Announces Updated Presentation Time for Upcoming Investor ConferenceGlobeNewswireCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it
- 5mo agoEDITEditas Medicine Announces Pricing of Up to $319.4 Million Public OfferingGlobeNewswireCAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an
- 5mo agoEDITEditas Medicine Announces Proposed Public OfferingGlobeNewswireCAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced
- 5mo agoEDITEditas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society CongressGlobeNewswireSingle dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple
- 6mo agoEDITEditas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual MeetingGlobeNewswireCAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting
- 6mo agoEDITEditas Medicine Announces First Quarter 2026 Results and Business UpdatesGlobeNewswireEDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data at upcoming
- 6mo agoEDITEditas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific ConferencesGlobeNewswireCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five
- 7mo agoEDITEditas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 InterferenceGlobeNewswireCAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the
- 8mo agoEDITEditas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business UpdatesGlobeNewswireLead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical trial in
- 8mo agoEDITEditas Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that
- 9mo agoCRSPEDITKBLBNTLACutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and MedicineGlobeNewswireDENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic diseases,
- 11mo agoEDITFDA Announces Leadership Appointments at Center for Drug Evaluation and ResearchFDA Press ReleasesThe U.S. Food and Drug Administration (FDA) today announced that Tracy Beth Høeg, M.D., Ph.D., has been appointed acting director of the Center for Drug Evaluation and Research (CDER). A physician and epidemiologist, Dr. Høeg was a Visiting Scholar at the Massachusetts Institute of Technology Sloan School of Management and practiced physical and interventional spine and sports medicine before join ...
- 1y agoEDITEditas Medicine Announces Third Quarter 2025 Results and Business UpdatesGlobeNewswireIn vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company on track to
- 1y agoEDITEditas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025GlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a
- 1y agoEDITEditas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual CongressGlobeNewswireCAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental,
- 1y agoEDITEditas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral
- 1y agoQUREVCYTHUMEDITHealthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention FocusPR NewswireAmerica's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...
- 1y agoEDITEditas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar (Transcript)Earnings Call Transcripts
- 1y agoEDITEditas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development CandidateGlobeNewswireEDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of
- 1y agoEDITEditas Medicine to Host Webinar Announcing Lead In Vivo Development CandidateGlobeNewswireCAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it
- 1y agoEDITEditas Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that
- 1y agoEDITEditas Medicine Announces Second Quarter 2025 Results and Business UpdatesGlobeNewswireCompany to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of
- 1y agoEDITEditas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in JuneGlobeNewswireAchieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports
- 1y agoEDITEditas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in JuneGlobeNewswirePreclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data
- 1y agoEDITEditas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswireData demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE,
- 1y agoEDITEditas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswireIn vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine,
- 1y agoEDITEditas Medicine Announces First Quarter 2025 Results and Business UpdatesGlobeNewswireCompany to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week
- 1y agoEDITEditas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal BoardGlobeNewswireCAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and
- 1y agoEDITEditas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in MayGlobeNewswireCAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it
- 1y agoEDITEditas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral
- 1y agoEDITEditas Medicine Announces Chief Financial Officer TransitionGlobeNewswireErick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a
- 1y agoEDITEditas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business UpdatesGlobeNewswireOn track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data
- 1y agoEDITEditas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in MarchGlobeNewswireCAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it
- 1y agoEDITEditas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic PrioritiesGlobeNewswireAchieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved
- 1y agoEDITEditas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading gene editing company, today announced that the Company's President and CEO Gilmore O'Neill, M.B., M.M.Sc., will present
- 1y agoEDITEditas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two YearsGlobeNewswireFocus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF
- 1y agoEDITEditas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual MeetingGlobeNewswirePoster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading gene editing company, will present
- 1y agoEDITEditas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)Earnings Call Transcripts
- 1y agoEDITEditas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)Earnings Call Transcripts